Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00062478Phase 2Completed

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Role: collaborator

NCT00477282Phase 3Completed

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Role: collaborator

NCT00062491Phase 2Completed

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Role: collaborator

NCT00097903Phase 1Completed

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Role: collaborator

All 4 trials loaded